24 Hrs
Source:
Financial Times
Novo Nordisk stock falls after trial setback
A Danish pharmaceutical company is attempting to expand beyond its popular obesity medications, Wegovy and Ozempic. The company is seeking new growth opportunities outside these core treatments.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)